Read by QxMD icon Read


A Carauleanu, R Socolov, V Rugina, O Gabia, Daniela Mihaela Carauleanu, Ivona Anghlcelache Lupascu, Demetra Socolov
AIM: Fibrocystic mastosis (FCM) is the most frequent benign breast lesion. Most treatments for fibrocystic mastosis are: hormonl, with beneficial results and non-hormonal, with fluctuating results. MATERIAL AND METHODS: A number of 210 cases were studied, which were divided into 7 groups. The study lasted for 9 months and it was carried out on the basis of a personal examination sheet. The following were monitored: age groups, mastodynia, reducing breast nodules, a significant reduction in the volume of the mastosic cysts, reducion of the fibrous tissue, medication tolerance...
April 2016: Revista Medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti Din Iaş̧i
Xiuxian Zhu, Hongjuan Ye, Yonglun Fu
Poor oocyte quality is a main concern for decreased reproductive outcomes in women with polycystic ovarian syndrome (PCOS) during controlled ovarian hyperstimulation (COH). A primary way to improve oocyte quality is to optimize the COH protocol. It was demonstrated that the viable embryo rate per oocyte retrieved in the Utrogestan and hMG protocol, a novel regimen based on frozen-thawed embryo transfer (FET), is statistically higher than that in the short protocol. Thus, a retrospective study was conducted to evaluate the endocrine characteristics and clinical outcomes in PCOS patients subjected to the Utrogestan and hMG protocol compared with those subjected to the short protocol...
July 2016: Medicine (Baltimore)
Arri Coomarasamy, Helen Williams, Ewa Truchanowicz, Paul T Seed, Rachel Small, Siobhan Quenby, Pratima Gupta, Feroza Dawood, Yvonne E Koot, Ruth Bender Atik, Kitty Wm Bloemenkamp, Rebecca Brady, Annette Briley, Rebecca Cavallaro, Ying C Cheong, Justin Chu, Abey Eapen, Holly Essex, Ayman Ewies, Annemieke Hoek, Eugenie M Kaaijk, Carolien A Koks, Tin-Chiu Li, Marjory MacLean, Ben W Mol, Judith Moore, Steve Parrott, Jackie A Ross, Lisa Sharpe, Jane Stewart, Dominic Trépel, Nirmala Vaithilingam, Roy G Farquharson, Mark David Kilby, Yacoub Khalaf, Mariëtte Goddijn, Lesley Regan, Rajendra Rai
BACKGROUND AND OBJECTIVES: Progesterone is essential to maintain a healthy pregnancy. Guidance from the Royal College of Obstetricians and Gynaecologists and a Cochrane review called for a definitive trial to test whether or not progesterone therapy in the first trimester could reduce the risk of miscarriage in women with a history of unexplained recurrent miscarriage (RM). The PROMISE trial was conducted to answer this question. A concurrent cost-effectiveness analysis was conducted...
May 2016: Health Technology Assessment: HTA
Xiuxian Zhu, Xiaole Zhang, Yonglun Fu
A major cause of cycle cancellation during controlled ovarian hyperstimulation (COH) in women undergoing in vitro fertilization (IVF) is the occurrence of premature luteinizing hormone (LH) surges. Steroidal preparations can modulate the secretion of gonadotropins (Gn); however, few studies using progesterone to inhibit the premature LH surges in COH have been published. The purpose of the study was to evaluate the oral delivery of progesterone soft capsules (Utrogestan) to prevent LH surges from the follicular phase and to compare cycle characteristics as well as to evaluate pregnancy outcomes in subsequent frozen-thawed embryo transfer (FET) cycles...
May 2015: Medicine (Baltimore)
V M Frolov, R A Kornienko, V Ia Starzhinskaia, M V Marchenko
The objective of the present study was to evaluate the influence of hormonal therapy used to correct the hormonal status of the pregnant women during different periods of gestation on the development of the nasal obstruction symptoms. A total of 53 case histories of the pregnant women (urban residents) were available for the analysis. In 2012, all the patients were under observation of an obstetrician-gyneciologist based at an outpatient setting. 16 of them (30.2%) suffered stuffness in the nose that was especially well pronounced during the II and III trimesters (37...
2014: Vestnik Otorinolaringologii
B Marinov, A Andreeva, M Cankova
UNLABELLED: In the recent years the rate of preterm deliveries has not been brought down despite of the new therapeutic management and medications. The aim of this scientific report is to share our algorithm of preterm delivery prevention. MATERIALS AND METHODS: Our trial consisted of 23 patients between 26 and 36 weeks of gestation diagnosed with preterm delivery, for a one year period - May 2010 to May 2011. The following therapeutic algorithm was applied: magnesium preparations, B2-mymetics, if no improvement was seen in 24 hour period we continued with Utrogestan, Calcium channel blockers, Indomethacin...
2011: Akusherstvo i Ginekologii︠a︡
Vlatka Tomic, Jozo Tomic, Djurdja Zigmundovac Klaic
The aim of the present study was to compare the efficacy and satisfaction rate of combined therapy of oral micronized progesterone capsules and vaginal progesterone gel versus monotherapy with vaginal progesterone gel in luteal support. A case-control study was performed on a total number of 370 women aged <45 years undergoing IVF-ET treatment. The patients received either combination of Crinone 8% vaginal gel, 90 mg daily dose and Utrogestan oral capsules 3 x 100 mg, or Crinone 8% vaginal gel, 90 mg daily...
December 2011: Gynecological Endocrinology
P Kostova, V Zlatkov
The aim of the present study was to establish the effectiveness of vaginal administration of micronized progesterone at 37 premenopausal women aged between 40-49 years (mean 44.5) with dysfunctional uterine bleeding. All women were subject of classical dilatation and curettage and after that micronized progesterone (Utrogestan) was applied vaginally 3 tablets 2 times per day, starting at 14 day of the menstrual cycle for 12 days. The control examination has been performed after finishing of 6 months therapy...
2009: Akusherstvo i Ginekologii︠a︡
Li-Jung Wang, Fu-Jen Huang, Fu-Tsai Kung, Pin-Yao Lin, Shiuh Young Chang, Kuo-Chung Lan
OBJECTIVE: To compare the efficacy of two vaginal progesterone formulations, Crinone gel and Utrogestan capsules, for luteal phase support in blastocyst stage embryo transfers. MATERIALS AND METHODS: We analyzed 460 consecutive cycles in patients undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)-blastocyst transfer (BT) treatment at our institution between January 2004 and December 2007. Patients applied either Crinone 8% vaginal gel (90 mg, once daily) or Utrogestan vaginal capsules (200 mg, four times daily) for luteal supplementation...
December 2009: Taiwanese Journal of Obstetrics & Gynecology
Jerome H Check
Supplementation of progesterone in the luteal phase and continuance of progesterone therapy during the first trimester has been found in several studies to have benefits in promoting fertility, preventing miscarriages and even preventing pre-term labor. Though it can be administered orally, intramuscularly or even sublingually, a very effective route with fewer side effects can be achieved by an intravaginal route. The first vaginal preparations were not made commercially but were compounded by pharmacies. This had the disadvantage of lack of control by the Food and Drug Administration (FDA) ensuring efficacy of the preparations...
August 2009: Therapeutics and Clinical Risk Management
S Bozhinova, P Bozhinov
Epilepsy is a disease, closely connected with sex-hormones and can lead to adverse repercussion on the reproductive health. The ovarial hormones influence excitation of neurocells membranes and have a lot of effects on brain, leading to provoking epileptic activity. The progesteron decrease and the estrogens increase the brain excitation, that's why estrogens (act like a proconvulsant) are proconvulsant and progesteron is anticonvulsant. The aim of this study is to evaluate therapeutic abilities of Utrogestan (micronising progesteron) for treatment of abortions and climacteric amplifications in women with epilepsy...
2005: Akusherstvo i Ginekologii︠a︡
Zh Karag'ozova, T Chernev, D Atanasova, E Pavlova, V Dimitrova, Iu Khranov, S Vragaleva
A retrospective study with 79 pregnant women was conducted. All of them were diagnosed as spontaneous abortion. The patients were separated in two group and the women have been treated in two schemes--51%--Utrogestan and 49%--Utrogestan and Profasi. The medication was applied only into the first trimester of the pregnancy. The duration of the therapy was 15.0 +/- 12.34 days. The mean gestational age in this study was 7.6 +/- 3.0 gestational weeks. Women with a first pregnancy and spontaneous abortion were excluded from the study...
2007: Akusherstvo i Ginekologii︠a︡
Selmo Geber, Ana Carolina Ferreira Moreira, Sálua Oliveira Calil de Paula, Marcos Sampaio
The use of progesterone for luteal phase support has been demonstrated to be beneficial in assisted reproduction cycles using gonadotrophin-releasing hormone analogues (GnRHa). Two micronized progesterone preparations are available for vaginal administration: capsules and gel. The objective of this study was to compare the efficacy of these two forms for luteal phase support in assisted reproduction cycles. A total of 244 couples undergoing IVF/intracytoplasmic sperm injection cycles were included in the study and were randomly allocated (sealed envelopes) into two groups: group 1 (122) received vaginal capsules of 200 mg of micronized progesterone (Utrogestan), 3 times daily, and group 2 (122) received micronized progesterone in gel (Crinone 8%), once daily...
February 2007: Reproductive Biomedicine Online
Velimir Simunic, Vlatka Tomic, Jozo Tomic, Dinko Nizic
OBJECTIVE: To compare the efficacy and tolerability of two different types of vaginal progesterone (P), Crinone 8% gel (Fleet Laboratories Ltd., Watford, United Kingdom) and Utrogestan capsules (Laboratories Besins International, Paris, France), used for luteal support after in vitro fertilization (IVF) cycles. DESIGN: Cohort study. SETTING: In Vitro Fertilization Polyclinic, Zagreb, Croatia. PATIENTS: A total of 285 women aged < or =37 years undergoing IVF-embryo transfer treatment...
January 2007: Fertility and Sterility
P Y S Tay, E A Lenton
This is a prospeve randomised study designed to clarify the impact of various luteal support regimes (HCG and progesterone) on progesterone profiles and pregnancy outcomes. This study involved subjects undergone down regulated. stimulated IVF cycles using various types of luteal support, namely: Cyclogest (n=35). Crinone gel (n=36), various doses of Utrogestan (n=55) and HCG (n=35). Various doses of Utrogestan (administered vaginally), Crinone gel (progesterone administered vaginally) and Cyclogest (progesterone administered rectally) supplementation induced similar end plasma progesterone concentrations ranging from 26 to 32 mmnl/l...
June 2005: Medical Journal of Malaysia
B Marinov, S Petkova, A Dukovski, G Georgiev, T Garnizov, V Manchev, G Kolarov, M Iunakova
Utrogestan is a modern progesterone, which shows maximal effectiveness with minimal side effects. It is a natural progesterone in micronized form, which makes it suitable for oral administration and vaginal application with same effectiveness. The aim of our retrospective study was to evaluate the therapeutical effects of Utrogestan in women with threatened abortion in the first trimester. Our experience dated from about one year and a half. Sixty eight women were treated for threatened abortion with a daily dose of 400 mg Utrogestan...
2004: Akusherstvo i Ginekologii︠a︡
Ricardo Baruffi, Ana Lucia Mauri, Claudia Guilhermino Petersen, Valéria Felipe, José Gonçalves Franco
PURPOSE: Vaginal progesterone administration starting on the day of oocyte retrieval induced a decrease in uterine contraction frequency on the day of embryo transfer (ET) as compared with preovulatory values. Uterine relaxation before ET is likely to improve outcome by avoiding displacement of the embryo from the uterine cavity (Fanchin, Righini, de Ziegler, Oliviennes, Ledée, Frydman: Fertil Steril 2001;75:1136-1140). The objective of the present study was to determine whether the early use of vaginal progesterone on the day of oocyte retrieval may alter the embryo implantation and pregnancy rates...
December 2003: Journal of Assisted Reproduction and Genetics
F Hermann, R Speich, M Schneemann
HISTORY AND ADMISSION FINDINGS: A 69-year-old man had a history of chronic abdominal pain and intermittent fever for more than 10 years. Due to acute epigastric pain and intermittent fever with night sweat for one week he was admitted for further investigation. On physical examination there was tenderness in the right upper and lower epigastrium without a palpable mass. INVESTIGATIONS: Laboratory figures showed signs of inflammation with a CRP of 103 mg/l. Leucocyte counts were normal without left shift...
June 20, 2003: Deutsche Medizinische Wochenschrift
B Nalbanski, K Tsekova, S Ivanov, I Kostov
A clinical trial is conducted with 32 pregnant patients with a history of sterility and infertility, uterine malformations as well as progesterone deficiency. The mean week of gestation is 9-10. All patients were treated with Utrogestan in the usual doses 2 x 100 mg for vaginal application. No side effects were observed which is encouraging to its routine use.
2002: Akusherstvo i Ginekologii︠a︡
Marc Germond, Paola Capelli, Giuliana Bruno, Sara Vesnaver, Alfred Senn, Nathalie Rouge, J Biollaz
OBJECTIVE: To compare the efficacy and the tolerability of two different vaginal formulations of micronized progesterone, Ellios and Utrogestan, used for luteal phase support after an in vitro fertilization (IVF) cycle. DESIGN: Cohort study. SETTING: Fertility center in a university hospital. PATIENT(S(: One hundred twenty-three women who underwent IVF/intracytoplasmic sperm injection (ICSI) stimulated cycles from October 1998 to March 2000, who had at least six follicles of > or =14 mm on the day of hCG administration...
February 2002: Fertility and Sterility
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"